After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Clearside Biomedical Inc. (CLSD) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.05, or 4.63%, to $1.13. The Clearside Biomedical Inc. has recorded 1,247 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
CLSD belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.08 and fluctuated between $1.3000 as its day high and $1.0600 as its day low. The current market capitalization of Clearside Biomedical Inc. is $71.60M. A total of 0.5 million shares were traded on the day, compared to an average of 243.45K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, CLSD has seen 4 BUY and 5 SELL insider trades, representing the acquisition of 51,158 and the disposition of 1,456,437 shares. Over the last 12 months, there were 6 BUYs and 5 SELLs from insiders. Insiders purchased 86,158 shares during that period but sold 1,456,437.
In the most recent transaction, Ciulla Thomas sold 13,700 shares of CLSD for 1.47 per share on Jan 20. After the transaction, the Chief Medical Officer now owns 291,890 company shares. In a previous transaction on Jan 19, LASEZKAY GEORGE M sold 20,030 shares at 1.46 per share. CLSD shares that CEO owns now total 484,577.
Among the insiders who sold shares, Deignan Charles A. disposed of 14,030 shares on Jan 19 at a per-share price of $1.50. This resulted in the Chief Financial Officer holding 363,472 shares of CLSD after the transaction. In another insider transaction, Ciulla Thomas sold 2,170 shares at $1.62 per share on Jan 10. Company shares held by the Chief Medical Officer now total 305,590.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for CLSD in the last 3 months, the mean price target is $5.80 with high estimates of $8.00 and low estimates of $4.00. In terms of 52-week highs and lows, CLSD has a high of $2.85 and a low of $0.98.
As of this writing, CLSD has an earnings estimate of -$0.13 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.11 per share and a lower estimate of -$0.14.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLSD is Overweight with a score of 4.75. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.